Use of Viabahn in the treatment of complications following endovascular procedures

Abstract

Introduction: Iatrogenic arterial injuries are frequent in several kind of procedures. The aim of our study was to evaluate the use of Viabanh stentgraft (Gore & associates, flagstaff, AR, USA) for the treatment of these complications. Material: This study reviewed retrospectively all Viabahn stentgrafts used in iliofemoral territory from February 2016 to April 2021. We described demographic characteristics, surveillance, patency and technical features of the surgery. Results: 25 cases were included, with a mean age 73 years (P25-75 53.5–83 The mean duration of follow-up was 23 ± 18.6 months, with a loss to follow-up of 8%. The survival rate after 6, 12 and 24 months was 96%, 91% and 69%, respectively. The lesions were secondary to cardiological intervention in 52% of the cases, oncological surgery in 20%, and neurological surgery in 12% of the cases. The artery most damaged was SFA (40%) followed by EIA (20%). Oversizing was 20% and 10% in proximal and distal landing respectively. The technical success rate was 100%. Global patency rate was 74% (17 cases). In 5 of the remaining 6 cases loss of patency was secondary to deliberate intraoperative arterial ligation to perform major amputation due to the progression of oncological disease. Up until the time of that operation, all had remained patent. Therefore, after excluding this cause of loss of patency, the global patency rate was seen to be 94%. Conclusion: The use of Viabahn for the treatment of arterial complications related to endovascular procedures and oncologic surgery appears to be safe and presents excelent rates of patency in the first year .